ResearchTreatments

WCLC 2025 Highlights: FLAURA2 trial

*September 2025*

At the WCLC 2025 Presidential Symposium Dr. David Planchard presented the Overall Survival (OS) results from the FLAURA2 trial. This pivotal study demonstrated that adding chemotherapy to Osimertinib significantly improves survival outcomes in first-line treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC), marking a major advancement in patient care. Here are selected expert reactions and highlights you shouldn’t miss.

Read more: https://oncodaily.com/insight/wclc-2025-363741